Meridian Bioscience (VIVO) 18.02 -0.03

Meridian Bioscience, Inc.
(VIVO) 18.02 -0.03

Last Trade:	17.99	Day Range:	17.45 - 18.04
Trade Time:	08:02PM	52wk Range:	14.81 - 27.37
Prev. Close:	18.02	Market Cap:	741.96M
Open:	17.79	Div Yield:	4.22
Volume:	291102	PE:
EPS:	0.67

The Latest On VIVO

UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform 1/31/12 9:52am

Wedbush Downgrades Meridian Bioscience to Underperform 1/31/12 7:29am

Meridian Bioscience Receives FDA Clearance For ImmunoCard C. difficile GDH Test 12/27/11 11:16am

Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene Group B Streptococcus 12/12/11 9:30am

Piper Jaffray Remains Underweight On Meridian Biosciences 11/10/11 12:53pm

Wedbush Lowers PT on Meridian Bioscience to $16 11/7/11 12:27pm

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue 9/20/11 2:19am

Piper Jaffray Underweight On Meridian Bioscience 9/13/11 6:51am

Piper Jaffray Initiates Meridian Bioscience At Underweight, $14 PT 9/13/11 5:12am

Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance 8/25/11 10:00am

Meridian Bioscience Launches ImmunoCard C. difficile GDH Assay in Europe 8/9/11 2:47pm

Biggest Losers in Pre-Market Trading 7/21/11 8:00am

UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform 1/31/12

Wedbush Downgrades Meridian Bioscience to Underperform 1/31/12

Meridian Bioscience Receives FDA Clearance For ImmunoCard C. difficile GDH Test 12/27/11

Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene Group B Streptococcus 12/12/11

Piper Jaffray Remains Underweight On Meridian Biosciences 11/10/11

Wedbush Lowers PT on Meridian Bioscience to $16 11/7/11

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue 9/20/11

Piper Jaffray Underweight On Meridian Bioscience 9/13/11

Piper Jaffray Initiates Meridian Bioscience At Underweight, $14 PT 9/13/11

Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance 8/25/11

Meridian Bioscience Launches ImmunoCard C. difficile GDH Assay in Europe 8/9/11

Biggest Losers in Pre-Market Trading 7/21/11

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue 9/20/11

Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows 7/20/11

Stocks to Watch for Monday 7/18/2011: Fresh 52 Week Highs and Lows 7/17/11

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROE 6/7/11

Top 4 Small-Cap Stocks In The Diagnostic Substance Industry With The Highest Operating Margin (AXK, BLUD, VIVO, NEOG) 5/16/11

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue (BLUD, NEOG, ABAX, VIVO) 4/14/11

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates (DBD, NEOG, VIVO, ABAX) 4/6/11

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Profit Margin (TRIB, AXK, BLUD, VIVO) 1/18/11

Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin (TRIB, BLUD, VIVO, QDEL) 11/17/10

Top 4 NASDAQ Stocks In The Healthcare Sector With The Highest Dividend Yield (CMED, VIVO, LNCR, ACET) 8/4/10

UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform 1/31/12

Wedbush Downgrades Meridian Bioscience to Underperform 1/31/12

Piper Jaffray Remains Underweight On Meridian Biosciences 11/10/11

Wedbush Lowers PT on Meridian Bioscience to $16 11/7/11

Piper Jaffray Underweight On Meridian Bioscience 9/13/11

Piper Jaffray Initiates Meridian Bioscience At Underweight, $14 PT 9/13/11

Canaccord Ups VIVO To Buy 3/24/11

William Blair & Co. Reiterates Market Perform on Meridian Bioscience (VIVO) 7/21/10

Jefferies Global Life Sciences Conference Takeaways; Diagnostics 6/14/10

William Blair & Company Maintains Meridian Bioscience (VIVO) Market Perform Rating 3/18/10

Hilliard Lyons Reiterates Long Term Buy Rating On VIVO 11/12/09

Trade VIVO
NOW!

Partner Headlines

Meridian Bioscience Inc. Reports Operating Results (10-Q) 2/9/12

Bearish MACD for VIVO - Tale of the Tape 2/9/12

The Best Yielding Healthcare Dividend Stocks with Fastest Earnings Growth 2/2/12

Meridian Intros HyperPAGE II Marker - Analyst Blog 1/19/12

10 High Margin Healthcare Dividend Shares 1/2/12

4 Dividend Darlings (HCII, PETS, TNH, VIVO) 12/21/11

FDA Clears Meridian illumigene GBS - Analyst Blog 12/14/11

12 Healthcare Dividend Stocks with Best Future EPS Growth 12/2/11

12 Dividend Healthcare Stocks with Best Future EPS Growth 12/2/11

Will Qiagen's Restructuring Address The Real Problems? (QGEN, SIAL, VIVO, GPRO, LIFE, ABT, ILMN, BDX, TMO, CPHD) 11/30/11

20 Dividend Achiever with Highest Earnings Forecasts 11/29/11

Press Releases

Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance 1/25/12 Business Wire Story

Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker 1/18/12 Business Wire Story

Meridian Bioscience Receives FDA Clearance For ImmunoCard® C. difficile GDH Test 12/27/11 Business Wire Story

Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group B Streptococcus 12/12/11 Business Wire Story

Meridian Bioscience Reports Fourth Quarter and Full-Year 2011 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance 11/10/11 Business Wire Story

Meridian Bioscience Launches ImmunoCard® C. difficile GDH Assay in Europe 8/30/11 Business Wire Story

Meridian Bioscience Establishes Direct Sales in Australia Through Bioline Australia 8/30/11 Business Wire Story

Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance 8/30/11 Business Wire Story

Get the latest VIVO stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Meridian Bioscience, Inc. stock price.

Meridian Bioscience, Inc. by YCharts